ELISA (EIA)
(ELISA of anti-CTLA-4 antibody on mouse CTLA-4-Fc fusion protein. Binding curves of the rabbit chimeric version of the anti-CTLA-4 antibody 9H10 (MBS488590; red line) and isotype control (anti-Fluorescein antibody MBS488041 4-4-20 (enhanced); blue line) to an ELISA plate coated with mouse CTLA-4-Fc fusion protein (Pr00155-1.9) at a concentration of 5ug/ml. A 3-fold serial dilution from 10,000 to 0.17 ng/ml was performed using MBS488590. For signal detection, a 1:4000 dilution of HRP-labelled anti-rabbit IgG1 antibody was used.)
anti-Mouse CTLA-4 Monoclonal Antibody | anti-CTLA-4 antibody
Anti-CTLA-4 [9H10]
ELISA (EIA)
(ELISA of anti-CTLA-4 antibody on mouse CTLA-4-Fc fusion protein. Binding curves of the rabbit chimeric version of the anti-CTLA-4 antibody 9H10 (MBS488590; red line) and isotype control (anti-Fluorescein antibody MBS488041 4-4-20 (enhanced); blue line) to an ELISA plate coated with mouse CTLA-4-Fc fusion protein (Pr00155-1.9) at a concentration of 5ug/ml. A 3-fold serial dilution from 10,000 to 0.17 ng/ml was performed using MBS488590. For signal detection, a 1:4000 dilution of HRP-labelled anti-rabbit IgG1 antibody was used.)
ELISA (EIA)
(ELISA of anti-CTLA-4 antibody on mouse CTLA-4-Fc fusion protein. Binding curves of the rabbit chimeric version of the anti-CTLA-4 antibody 9H10 (MBS488590; red line) and isotype control (anti-Fluorescein antibody MBS488041 4-4-20 (enhanced); blue line) to an ELISA plate coated with mouse CTLA-4-Fc fusion protein (Pr00155-1.9) at a concentration of 5ug/ml. A 3-fold serial dilution from 10,000 to 0.17 ng/ml was performed using MBS488590. For signal detection, a 1:4000 dilution of HRP-labelled anti-rabbit IgG1 antibody was used.)
This antibody was raised by immunising Syrian hamsters with Staphylococcus A bacteria coated in CTLA-4, isolating B cells from the immunised hamsters and fusing these with the P3X3.Ag8.653 myeloma line to produce stable hybridomas.
Note on publication: Describes the original generation and characterisation of this antibody.
NCBI and Uniprot Product Information
NCBI Description
This gene is a member of the immunoglobulin superfamily, and encodes a protein that functions as a negative regulator of T-cell responses. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. [provided by RefSeq, Aug 2013]
Uniprot Description
CTLA-4: Inhibitory receptor acting as a major negative regulator of T-cell responses. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28. Genetic variation in CTLA4 influences susceptibility to systemic lupus erythematosus (SLE). SLE is a chronic, inflammatory and often febrile multisystemic disorder of connective tissue. It affects principally the skin, joints, kidneys and serosal membranes. SLE is thought to represent a failure of the regulatory mechanisms of the autoimmune system. Genetic variations in CTLA4 may influence susceptibility to Graves disease, an autoimmune disorder associated with overactivity of the thyroid gland and hyperthyroidism. Genetic variation in CTLA4 is the cause of susceptibility to diabetes mellitus insulin-dependent type 12 (IDDM12). A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical fetaures are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels. Genetic variation in CTLA4 is the cause of susceptibility to celiac disease type 3 (CELIAC3). It is a multifactorial disorder of the small intestine that is influenced by both environmental and genetic factors. It is characterized by malabsorption resulting from inflammatory injury to the mucosa of the small intestine after the ingestion of wheat gluten or related rye and barley proteins. In its classic form, celiac disease is characterized in children by malabsorption and failure to thrive. 4 isoforms of the human protein are produced by alternative splicing.
Protein type: Immunoglobulin superfamily; Membrane protein, integral
Cellular Component: Golgi apparatus; membrane; perinuclear region of cytoplasm; plasma membrane; integral to membrane; clathrin-coated endocytic vesicle; external side of plasma membrane
Biological Process: B cell receptor signaling pathway; negative regulation of T cell proliferation; positive regulation of apoptosis; immune system process; negative regulation of regulatory T cell differentiation; negative regulation of immune response; immune response; negative regulation of B cell proliferation; response to DNA damage stimulus
Research Articles on CTLA-4
Similar Products
Product Notes
The CTLA-4 ctla4 (Catalog #AAA488589) is an Antibody produced from Hamster (Armenian) and is intended for research purposes only. The product is available for immediate purchase. The Anti-CTLA-4 [9H10] reacts with Mouse and may cross-react with other species as described in the data sheet. AAA Biotech's CTLA-4 can be used in a range of immunoassay formats including, but not limited to, Neutralisation, Western Blot (WB), Flow Cytometry (FC/FACS), ELISA (EIA), Proliferation Assays. CTLA-4 is upregulated on T cells following their activation, and acts as a negative regulator of T cell responses; CTLA-4 binds to the B7 molecules CD80 and 86, resulting in the delivery of an inhibitory signal, and consequent downregulation of T cell-mediated immunity. Administration of 9H10 blocks the interaction between CTLA-4 on the T cell surface and CD80 and CD86. This promotes the activation of effector T cells and stimulates the immune response raised against weak antigens, including tumour antigens. While this antibody alone does not enhance T cell proliferation, it does significantly increase T cell proliferation when administered together with anti-CD28 (clone 37.51) (Krummel & Allison, 1995), anti-OX40 and anti-GITR (Houot & Levy, 2009). Blocking CTLA-4 induces T cell anti-tumour immunity in animal models, both by suppressing regulatory T cell activity and directly promoting CD8+ T cell effector function (Peggs et al, 2009). In transgenic murine models of prostate cancer, the use of a CTLA-4 blockade in conjunction with an irradiated tumour cell vaccine stimulates an immune response against primary tumours, and results in a significant reduction in tumour incidence (Hurwitz et al, 2000). Similarly, in murine melanoma models, CTLA-4 blockage, in combination with CD40 stimulation and adenoviral vaccination, can elicit complete regression (Sorensen et al, 2010). In murine models of pancreatic ductal adenocarcinoma, 9H10 has also been shown to induce T cell-dependent tumour regressions (Vonderheide et al, 2015). Priming the T cell response with CD40 mAbs or chemotherapy reversed the resistance to 9H10 and RMP1-14 observed in well-established tumours. Additionally, this antibody has been used to detect CTLA-4 using ELISA (Krummel & Allison, 1995) and to stain CTLA-4-expressing cells (Deeths et al, 1999). Researchers should empirically determine the suitability of the CTLA-4 ctla4 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "CTLA-4, Monoclonal Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
